Tagged with ART

Opinion DataArt’s Daniel Piekarz looks at how machine learning and artificial intelligence can play into the important task of drug repurposing, potentially providing solutions to the most pressing healthcare concerns of today, including the COVID-19 pandemic.   “Standing on the shoulders of giants” is a metaphor, made famous by Isaac Newton,…

Cell & Gene Therapy Two years on from the introduction of Novartis Oncology’s CAR-T therapy to Europe, Emnuele Ostuni, the firm’s European head of cell and gene therapy, spoke to PharmaBoardroom about the pioneering product’s journey to market, what has been learnt along the way, and how his team has worked to assuage concerns…

Cell & Gene Therapy Emanuele Ostuni, Novartis Oncology’s head of cell and gene therapy for Europe, gives an overview of the introduction of the company’s CAR-T therapy to Europe, the work still to be done to get this product to more patients who need it across the continent, and the future of cell and…

Coronavirus Sophia Ononye-Onyia outlines the key failings in the USA’s response to the coronavirus outbreak and why greater numbers of inter-industry partnerships and increased technological uptake are key to fighting this crisis and reframing the US life sciences industry of the future.   Imagine if we invested billions in epidemiological surveillance…

Morocco Saad Kanbris, who has been heading Novartis operations in Morocco, Tunisia & Libya since January 2018, discusses the importance of ‘the context’ and temporality while analyzing the improvement and the next steps for the Moroccan market and the region he manages.   It makes no sense to grow if there…

Sweden Sweden’s USD 4.8 billion pharmaceutical market, its population size of 10 million and marginal positioning on the northerly fringe of the European Union all belie a legacy as a real titan of life sciences.* The country that has introduced some of the most impactful healthcare inventions of the 20th century…

Mexico Earlier in 2020, PharmaBoardroom sat down with several key stakeholders in the Mexican healthcare and life sciences industry, from the leaders of multinational affiliates, start-up entrepreneurs, association heads, and key opinion leaders. Here, we round up three of their most talked about topics.   Government  One of the most talked-about…

UK With Brexit now confirmed, the UK government has been playing up the country’s scientific credentials. The aim is to cement the UK’s position as one of the world’s top life science investment destinations and multinational pharma firms including Novartis are already taking note.   “Tangible Opportunity” In February 2020, the…

Artificial Intelligence Artificial intelligence (AI) is increasingly being utilised in the drug discovery process, with the latest breakthrough being the development of an antibiotic that is powerful enough to combat resistant bacteria strains via a deep learning algorithm.   AI has the power to enable biopharmaceutical companies to reduce costs and improve…

Mexico Diego Ruiz, CEO and co-founder of Eseotr3s Pharma shares his entrepreneurial background and the motivation for establishing Eseotr3s Pharma; their focus on flexibility and quality; their international operations and network, with offices in Spain and India; and his outlook for the Mexican pharmaceutical industry in 2020.   The government has…

Romania Jorge Levinson, head of Bayer Pharmaceuticals Romania and Moldova, reveals his first impressions of Romania and the untapped potential it offers to the company. He shares his insights on how close-knit partnerships with the government, patient and medical associations are key and discloses his ambition to create an organisational culture…

Czech Republic A cross-industry push for better and broader access to innovative treatments is underway in the Czech Republic. Ripe for reform is the country’s orphan drug legislation as no standard pathway for their assessment, pricing and reimbursement currently exists.   [For cancer treatment the country has been] quite successful in moving…